Penumbra (PEN) Cash & Equivalents Growth (1y) (2015 - 2026)
Penumbra (PEN) Cash & Equivalents Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.46 Bn | 193.86 Bn | 7.27 Bn | -26.57% |
| 2 | Stryker | 127.41 Bn | 123.93 Bn | 4.50 Bn | 42.78% |
| 3 | Medtronic | 118.87 Bn | 109.65 Bn | 6.41 Bn | -12.13% |
| 4 | Boston Scientific | 73.47 Bn | 72.93 Bn | 3.85 Bn | 0.94% |
| 5 | Edwards Lifesciences | 51.95 Bn | 47.69 Bn | 1.35 Bn | -11.19% |
| 6 | Dexcom | 34.30 Bn | 32.35 Bn | 830.00 Mn | -4.66% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | -44.03% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.02 Bn | 4.55 Bn | 19.49% |
| 9 | Steris | 23.04 Bn | 22.55 Bn | 684.20 Mn | 72.43% |
| 10 | Penumbra | 12.78 Bn | 12.13 Bn | 264.94 Mn | -51.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -51.33% |
| Mar 31, 2026 | -35.84% |
| Dec 31, 2025 | -42.39% |
| Sep 30, 2025 | 14.46% |
| Jun 30, 2025 | 46.28% |
| Mar 31, 2025 | 68.55% |
| Dec 31, 2024 | 93.69% |
| Sep 30, 2024 | 178.37% |
| Jun 30, 2024 | 152.55% |
| Mar 31, 2024 | 135.63% |
| Dec 31, 2023 | 139.75% |
| Sep 30, 2023 | 83.72% |
| Jun 30, 2023 | 96.05% |
| Mar 31, 2023 | 38.91% |
| Dec 31, 2022 | 17.65% |
| Sep 30, 2022 | -17.27% |
| Mar 31, 2022 | 22.52% |
| Dec 31, 2021 | -14.77% |
| Sep 30, 2021 | -17.26% |
| Mar 31, 2021 | -23.22% |